Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc.

In a report released today, Roger Song from Jefferies maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of...

Jefferies Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Biotech Structure Therapeutics’ ($GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped competing offerings from ...

Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk

Shares of Texas-based biotech firm iBio ($IBIO) have climbed as high as 50% over the past 24 hours. This follows a 39.17% gain on Monday and an add...

Why is Biotech Stock iBio Up over 50%?

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Structure Therapeutics, Inc. Sponsored ADR (GPCR – R...

Analysts’ Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Sionna Therapeutics, Inc. (SION)

Clear Street analyst Kaveri Pohlman maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $99.00. P...

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Clear Street

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has shared an announcement. On December 8, 2025, Structure Therapeutics announced positive r...

Structure Therapeutics Announces Positive Clinical Trial Results

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe that the following s...

These 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025

In a report released yesterday, Prakhar Agrawal from Cantor Fitzgerald maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with ...

Market Cap	$4.05B	P/E Ratio	N/A
52W High	$94.90	52W Low	$13.22
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	65.9%
Overall Score	54	Value Score	50
Quality Score	31	Technical Score	83

EPS Current Est	$-1.39	EPS Next Est	$-1.27
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GPCR	$67.06	-0.56%	1.50M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GPCR	$67.06	-0.6%	1.50M
3
4
5
6

GPCR

GPCR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Structure Therapeutics Inc. Data in Excel

Get Structure Therapeutics Inc. Data in Excel